Earnings Analysis July 29, 2026

Boston Scientific ($BSX) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat Estimates, Full-Year Guidance Cut

Earnings Scorecard

Revenue: $5.442 billion (+7.5% year-over-year, estimate $5.368 billion) ✅ Beat

EPS (Earnings Per Share): Adjusted $0.86 (estimate $0.83) ✅ Beat

Guidance: Lowered — full-year revenue growth 5.5–6.5%, adjusted EPS $3.28–3.32

Stock Reaction: After-hours +0.93% ($46.49) — as of 07-29 20:52 KST

The Positives

Adjusted earnings beat: Adjusted EPS of $0.86 topped the $0.83 estimate

Revenue also beat: Revenue of $5.442 billion rose 7.5% year-over-year, exceeding expectations

Cardiovascular led growth: Cardiovascular revenue grew 8.3% year-over-year, driving overall growth

Boston Scientific is a large medical-technology company that makes devices for cardiovascular, respiratory, digestive, neurological, and urological conditions. Q2 revenue of $5.442 billion was up 7.5% on a reported basis from $5.061 billion a year earlier, and up 7.0% on both an operational and organic basis (excluding FX impact), landing at the top of the company's own guidance range (reported 5.5–7.5%, organic 5–7%). It also cleared the analyst revenue estimate of $5.368 billion.

By segment, Cardiovascular brought in $3.624 billion (+8.3%), accounting for roughly two-thirds of the total and leading growth, while Endoscopy (+7.6%) and Neuromodulation (+12.7%) also performed solidly. Adjusted EPS of $0.86 exceeded the prior-year $0.75, the company's guidance of $0.82–0.84, and the market estimate of $0.83. GAAP diluted EPS was $0.61. Regionally, Asia-Pacific (+11.2%) and Latin America/Canada (+22.4%) stood out.

The Negatives

Full-year guidance lowered: Cut the full-year revenue growth and adjusted EPS outlooks

Q3 growth slowdown hinted: Q3 revenue growth guidance of 3–5% is below Q2

Urology segment weak: Urology revenue growth came in at just 1.1%, marking a deceleration

Compared with the full-year outlook issued just one quarter ago (Q1), the magnitude of the cut is clear. Revenue growth had been guided at 7.0–8.5% on a reported basis and 6.5–8.0% on an organic basis, with adjusted EPS of $3.34–3.41. This time, those ranges were lowered to 5.5–6.5%, 5–6%, and $3.28–3.32, respectively. Q2 sold well, but the company's view on second-half growth pace has become more cautious.

Q3 guidance of roughly 3–5% revenue growth and $0.80–0.82 adjusted EPS signals a deliberate moderation in pace relative to Q2 results. Within MedSurg (Surgery/Percutaneous Intervention), Urology grew only 1.1%, pointing to uneven portfolio growth, and Europe/Middle East/Africa came in relatively soft at 4.2% on an operational basis after adjusting for FX.

What Management Said

CEO Mike Mahoney credited the team for delivering a solid quarter amid a dynamic environment and emphasized disciplined execution and prioritized investment in high-impact opportunities. The tone also reaffirmed confidence in long-term growth, built on a category leadership strategy and meaningful innovation for patients and physicians.

That said, the numbers in the earnings release point to a message closer to "this quarter was good, but the outlook ahead is more conservative." Q2 revenue and adjusted earnings both topped company guidance and Street estimates, yet full-year and Q3 guidance was lowered. At the same time, the company cited medium- to long-term growth pillars — including the FARAPULSE pulsed-field ablation clinical results, the Mirus equity investment with its transcatheter aortic valve replacement option, and the completion of the $2 billion share buyback — appearing to signal a combination of "near-term bar reset and long-term pipeline" simultaneously.

Market Reaction and What to Watch Next

The market digested the beat-and-cut combination at once, tilting mildly positive without a clear directional move. The numbers themselves were solid, but the visibly slower second-half growth pace appears to have capped the upside. The after-hours price action immediately following the release looks less like outright cheer or a sell-the-news drop, and more like "confirmed, then wait-and-see."

Watch how close Q3 revenue growth comes to the top end of guidance (5%) and whether the second-half slowdown proves transitory.

Track whether revenue contribution from growth products such as Cardiovascular and FARAPULSE continues at a pace that can reverse the full-year guidance cut.

Whether the full-year adjusted EPS range of $3.28–3.32 is held or re-raised stands as the key focal point for the next earnings release.